Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas

This article was originally published in PharmAsia News

Executive Summary

Just days after the publication of promising data concerning its antibiotic drug candidate fidaxomicin, Optimer Pharmaceuticals Inc. has licensed the compound to Astellas Pharma Europe Ltd. to treat Clostridium difficile infections in Europe and additional territories

You may also be interested in...

Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance

Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area

Theravance Gets To Market With Vibativ, But HAP Indication Could Be Pushed To 2010

Theravance expects an FDA advisory committee review for Vibativ in hospital acquired pneumonia; product partnered with Astellas is approved for complicated skin infections.

Optimer Rides High After OPT-80 C. Diff Trial Success

Phase III data show antibiotic non-inferior to Vancocin; additional trial results due mid-2009 with an NDA filing by year’s end.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts